RANKL, denosumab, and giant cell tumor of bone

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 397-403

  Thomas, David M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

denosumab; giant cell tumor of bone; RANKL

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; ZOLEDRONIC ACID;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; HUMAN; INFECTION; JAW OSTEONECROSIS; NONHUMAN; OSTEOCLASTOMA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; GIANT CELL TUMOR OF BONE; HUMANS; RANK LIGAND;

EID: 84862139450     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328354c129     Document Type: Review

References (103)

1. WHO. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
2. Guo W, Xu W, Huvos AG, et al. Comparative frequency of bone sarcomas among different racial groups. Chin Med J (Engl) 1999; 112: 1101-1104.
3. Sung HW, Kuo DP, Shu WP, et al. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am 1982; 64:755-761. (Pubitemid 12090286)
4. Unni KK. Dahlin's bone tumors: general aspects and data on 11 087 cases. New York: Lippincott-Raven; 1996.
5. Werner M. Giant cell tumour of bone: morphological, biological and histogenetical aspects. Int Orthopaed 2006; 30:484-489. (Pubitemid 44900556)
6. Won KY, Kalil RK, Kim YW, Park YK. RANK signalling in bone lesions with osteoclast-like giant cells. Pathology 2011; 43:318-321.
7. Ushiku T, Shinozaki A, Uozaki H, et al. Gastric carcinoma with osteoclast-like giant cells. Lymphoepithelioma-like carcinoma with Epstein-Barr virus infection is the predominant type. Pathol Int 2010; 60:551-558.
8. Taylor R, Kashima TG, Knowles H, et al. Osteoclast formation and function in pigmented villonodular synovitis. J Pathol 2011; 225:151-156.
9. Liu B, Yu SF, Li TJ. Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med 2003; 32:367-375. (Pubitemid 36781536)
10. Itonaga I, Schulze E, Burge PD, et al. Phenotypic characterization of mononuclear and multinucleated cells of giant cell reparative granuloma of small bones. J Pathol 2002; 198:30-36. (Pubitemid 34966204)
11. Itonaga I, Hussein I, Kudo O, et al. Cellular mechanisms of osteoclast formation and lacunar resorption in giant cell granuloma of the jaw. J Oral Pathol Med 2003; 32:224-231. (Pubitemid 36604018)
12. Gibbons CL, Sun SG, Vlychou M, et al. Osteoclast-like cells in soft tissue leiomyosarcomas. Virchows Arch 2010; 456:317-323.
13. Domovitov SV, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 2010; 17:694-701.
14. Beebe-Dimmer JL, Cetin K, Fryzek JP, et al. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors 2009; 1:e52.
15. Campanacci M, Baldini N, Boriani S, Sudanese A. Giant-cell tumor of bone. J Bone Joint Surg Am 1987; 69:106-114. (Pubitemid 17030377)
16. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980; 153:106-120. (Pubitemid 11217753)
17. Ng ES, Saw A, Sengupta S, et al. Giant cell tumour of bone with late presentation: review of treatment and outcome. J Orthop Surg (Hong Kong) 2002; 10:120-128. (Pubitemid 36193914)
18. Dominkus M, Ruggieri P, Bertoni F, et al. Histologically verified lung metastases in benign giant cell tumours-14 cases from a single institution. Int Orthop 2006; 30:499-504. (Pubitemid 44900558)
19. Osaka S, Toriyama M, Taira K, et al. Analysis of giant cell tumor of bone with pulmonary metastases. Clin Orthop Relat Res 1997; 335:253-261. (Pubitemid 27074504)
20. Anract P, De Pinieux G, Cottias P, et al. Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop 1998; 22:19-26. (Pubitemid 28132804)
21. Kapoor SK, Jain V, Agrawal M, et al. Primary malignant giant cell tumor of bone: a series of three rare cases. J Surg Orthop Adv 2007; 16:89-92.
22. Rendina D, Mossetti G, Soscia E, et al. Giant cell tumor and Paget's disease of bone in one family: geographic clustering. Clin Orthop Relat Res 2004; 421:218-224. (Pubitemid 38579742)
23. Jacobs TP, Michelsen J, Polay JS, et al. Giant cell tumor in Paget's disease of bone: familial and geographic clustering. Cancer 1979; 44:742-747. (Pubitemid 10233788)
24. Tombridge TL. Familial giant cell reparative granuloma of the mandible ('cherubism'). Am J Clin Pathol 1962; 37:196-203.
25. Lee SM, Cooper JC. Noonan syndrome with giant cell lesions. Int J Paediatr Dent 2005; 15:140-145. (Pubitemid 40469996)
26. Kaugars GE, Niamtu J 3rd, Svirsky JA. Cherubism: diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors. Oral Surg Oral Med Oral Pathol 1992; 73:369-374.
27. De Lange J, van der Akker HP. Noonan syndrome with giant cell lesions. Int J Paediatr Dent 2006; 16:69. (Pubitemid 43455159)
28. Ueki Y, Tiziani V, Santanna C, et al. Mutations in the gene encoding c-Ablbinding protein SH3BP2 cause cherubism. Nat Genet 2001; 28:125-126. (Pubitemid 32538054)
29. Khosla VM, Korobkin M. Cherubism. Am J Dis Child 1970; 120:458-461.
30. Ruggieri M, Pavone V, Polizzi A, et al. Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87:67-72.
31. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010; 1:2-26.
32. Athanasou NA, Quinn J, Ferguson DJ, McGee JO. Bone resorption by macrophage polykaryons of giant cell tumour of tendon sheath. Br J Cancer 1991; 63:527-533.
33. Ohsaki Y, Takahashi S, Scarcez T, et al. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 1992; 131:2229-2234.
34. Skubitz KM, Cheng EY, Clohisy DR, et al. Gene expression in giant-cell tumors. J Lab Clin Med 2004; 144:193-200.
35. Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005; 167:117-128. (Pubitemid 40884775)
36. Geldyyev A, Koleganova N, Piecha G, et al. High expression level of bone degrading proteins as a possible inducer of osteolytic features in pigmented villonodular synovitis. Cancer Lett 2007; 255:275-283. (Pubitemid 47268645)
37. Atkins GJ, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000; 15:640-649. (Pubitemid 30174018)
38. Murata A, Fujita T, Kawahara N, et al. Osteoblast lineage properties in giant cell tumors of bone. J Orthop Sci 2005; 10:581-588. (Pubitemid 41712706)
39. Nishimura M, Yuasa K, Mori K, et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J Orthop Res 2005; 23:979-987. (Pubitemid 41245419)
40. Alberghini M, Kliskey K, Krenacs T, et al. Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 2010; 456:97-103.
41. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med 2004; 45:1528-1535. (Pubitemid 47618507)
42. Vult von Steyern F, Bauer HC, Trovik C, et al. Treatment of local recurrences of giant cell tumour in long bones after curettage and cementing. A Scandinavian Sarcoma Group study. J Bone Joint Surg Br 2006; 88:531-535.
43. Turcotte RE, Wunder JS, Isler MH, et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 2002; 397:248-258. (Pubitemid 34442036)
44. Becker WT, Dohle J, Bernd L, et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 2008; 90:1060-1067. (Pubitemid 351632651)
45. Klenke FM, Wenger DE, Inwards CY, et al. Recurrent giant cell tumor of long bones: analysis of surgical management. Clin Orthop Relat Res 2011; 469:1181-1187.
46. Zhen W, Yaotian H, Songjian L, et al. Giant-cell tumour of bone. The longterm results of treatment by curettage and bone graft. J Bone Joint Surg Br 2004; 86:212-216.
47. Durr HR, Maier M, Jansson V, et al. Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone. Eur J Surg Oncol 1999; 25:610-618.
48. Cheng EY, Zwolak P, Manivel C, et al. Zoledronic acid release from polymethylmethacrylate carrier and in vitro activity against giant cell tumor of bone. In: Musculoskeletal Tumor Society Annual Meeting. Phoenix: Musculoskeletal Tumor Society; 2008. p. 67.
49. Malawer MM, Bickels J, Meller I, et al. Cryosurgery in the treatment of giant cell tumor. A long-term follow up study. Clin Orthop Relat Res 1999; 359:176-188. (Pubitemid 29110738)
50. Gitelis S, Mallin BA, Piasecki P, Turner F. Intralesional excision compared with en bloc resection for giant-cell tumors of bone. J Bone Joint Surg Am 1993; 75:1648-1655. (Pubitemid 24036441)
51. Labs K, Perka C, Schmidt RG. Treatment of stages 2 and 3 giant-cell tumor. Arch Orthop Trauma Surg 2001; 121:83-86. (Pubitemid 32124004)
52. Yu XC, Xu M, Song RX, et al. Long-term outcome of giant cell tumors of bone around the knee treated by en bloc resection of tumor and reconstruction with prosthesis. Orthop Surg 2010; 2:211-217.
53. Caudell JJ, Ballo MT, Zagars GK, et al. Radiotherapy in the management of giant cell tumor of bone. Int J Radiat Oncol Biol Phys 2003; 57:158-165. (Pubitemid 36959751)
54. Chakravarti A, Spiro IJ, Hug EB, et al. Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 1999; 81:1566-1573.
55. Feigenberg SJ, Marcus Jr RB, Zlotecki RA, et al. Radiation therapy for giant cell tumors of bone. Clin Orthop Relat Res 2003; 401:207-216. (Pubitemid 36667279)
56. Malone S, O'Sullivan B, Catton C, et al. Long-term follow-up of efficacy and safety of megavoltage radiotherapy in high-risk giant cell tumors of bone. Int J Radiat Oncol Biol Phys 1995; 33:689-694.
57. Ruka W, Rutkowski P, Morysinski T, et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int J Radiat Oncol Biol Phys 2010; 78:494-498.
58. Roeder F, Timke C, Zwicker F, et al. Intensity modulated radiotherapy (IMRT) in benign giant cell tumors-a single institution case series and a short review of the literature. Radiat Oncol 2010; 5:18.
59. Blattmann C, Oertel S, Schulz-Ertner D, et al. Nonrandomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with nonresectable osteosarcoma. BMC Cancer 2010; 10:96.
60. Martin C, McCarthy EF.Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J 2010; 30:69-75.
61. Ruggieri P, Mavrogenis AF, Ussia G, et al. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor. Clin Orthop Relat Res 2010; 468:2954-2961.
62. Onishi H, Kaya M, Wada T, et al. Giant cell tumor of the sacrum treated with selective arterial embolization. Int J Clin Oncol 2010; 15 :416-419.
63. Santiago FR, Del Mar Castellano Garcia M, Montes JL, et al. Treatment of bone tumours by radiofrequency thermal ablation. Curr Rev Musculoskelet Med 2009; 2:43-50.
64. Bertoni F, Present D, Enneking WF. Giant-cell tumor of bone with pulmonary metastases. J Bone Joint Surg Am 1985; 67:890-900. (Pubitemid 15240314)
65. Faisham WI, Zulmi W, Halim AS, et al. Aggressive giant cell tumour of bone. Singapore Med J 2006; 47:679-683. (Pubitemid 44196854)
66. Kaiser U, Neumann K, Havemann K. Generalised giant-cell tumour of bone: successful treatment of pulmonary metastases with interferon alpha, a case report. J Cancer Res Clin Oncol 1993; 119:301-303. (Pubitemid 23055433)
67. Maloney WJ, Vaughan LM, Jones HH, et al. Benign metastasizing giant-cell tumor of bone. Report of three cases and review of the literature. Clin Orthop Relat Res 1989; 243:208-215. (Pubitemid 19165388)
68. Stewart DJ, Belanger R, Benjamin RS. Prolonged disease-free survival following surgical debulking and high-dose cisplatin/doxorubicin in a patient with bulky metastases from giant cell tumor of bone refractory to 'standard' chemotherapy. Am J Clin Oncol 1995; 18:144-148.
69. Skubitz KM, Manivel JC. Giant cell tumor of the uterus: case report and response to chemotherapy. BMC Cancer 2007; 7:46.
70. Kaban LB, Troulis MJ, Wilkinson MS, et al. Adjuvant antiangiogenic therapy for giant cell tumors of the jaws. J Oral Maxillofac Surg 2007; 65:2018-2024; discussion 2024. (Pubitemid 47404734)
71. Balke M, Campanacci L, Gebert C, et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone. BMC Cancer 2010; 10:462.
72. Nishisho T, Hanaoka N, Endo K, et al. Locally administered zoledronic acid therapy for giant cell tumor of bone. Orthopedics 2011; 34:e312-e315.
73. Fujimoto N, Nakagawa K, Seichi A, et al. A new bisphosphonate treatment option for giant cell tumors. Oncol Rep 2001; 8:643-647. (Pubitemid 33758469)
74. Arpornchayanon O, Leerapun T. Effectiveness of intravenous bisphosphonate in treatment of giant cell tumor: a case report and review of the literature. J Med Assoc Thai 2008; 91:1609-1612.
75. Tse LF, Wong KC, Kumta SM, et al. Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone 2008; 42:68-73. (Pubitemid 350297173)
76. Walker DG. Congenital osteopetrosis in mice cured by parabiotic union with normal siblings. Endocrinology 1972; 91:916-920.
77. Walker DG. Control of bone resorption by hematopoietic tissue. The induction and reversal of congenital osteopetrosis in mice through use of bone marrow and splenic transplants. J Exp Med 1975; 142:651-663.
78. Udagawa N, Takahashi N, Akatsu T, et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc Natl Acad Sci USA 1990; 87:7260-7264.
79. Wiktor-Jedrzejczak WW, Ahmed A, Szczylik C, Skelly RR. Hematological characterization of congenital osteopetrosis in op/op mouse. Possible mechanism for abnormal macrophage differentiation. J Exp Med 1982; 156:1516-1527. (Pubitemid 13232211)
80. Takahashi N, Akatsu T, Udagawa N, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123:2600-2602.
81. Suda T, Udagawa N, Nakamura I, et al. Modulation of osteoclast differentiation by local factors. Bone 1995; 17:87S-91S.
82. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332:305-311.
83. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424. (Pubitemid 29453612)
84. Kim N, Odgren PR, Kim DK, et al. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci USA 2000; 97:10905-10910.
85. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319. (Pubitemid 27199902)
86. Schwartz HS, Jenkins RB, Dahl R, Dewald GW. Cytogenetic analyses in giant-cell tumors of bone. Clin Orthop Relat Res 1989; 240:250-260. (Pubitemid 19072147)
87. Moskovszky L, Szuhai K, Krenacs T, et al. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis. Genes Chromosomes Cancer 2009; 48: 468-479.
88. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giantcell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006; 103:690-695. (Pubitemid 43153087)
89. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-176. (Pubitemid 28180851)
90. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-323.
91. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24:182-195.
92. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-831. (Pubitemid 43290920)
93. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-765.
94. Rifkin WD. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:2390-2391.
95. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745-755.
96. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol2010; 28:5132-5139.
97. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29:1125-1132.
98. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379:39-46.
99. Bridgeman MB, Pathak R. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review. Clin Ther 2011; 33:1547-1559.
100. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int 2012; 22:435-446.
101. Toulis KA, Anastasilakis AD. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2010; 21:1963-1964.
102. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int 2012; 23:327-337.
103. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010; 11:275-280.